Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.37 USD | -2.46% | -3.11% | -15.18% |
Business Summary
Number of employees: 37
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Central Nervous System Therapies
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -120.50% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -120.50% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shawn Singh
CEO | Chief Executive Officer | 61 | 99-12-31 |
Cynthia Anderson
DFI | Director of Finance/CFO | 55 | 23-08-20 |
Joshua Prince
COO | Chief Operating Officer | 54 | 21-10-31 |
Ross Baker
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-30 |
Ann Cunningham
BRD | Director/Board Member | 56 | 19-01-09 |
Mark McPartland
IRC | Investor Relations Contact | 58 | 16-10-03 |
Jessica Haskell
SEC | Corporate Secretary | - | 22-07-31 |
Human Resources Officer | - | 21-12-31 | |
Erik Berglund
LAW | General Counsel | - | 21-01-31 |
Louis Monti
PRN | Corporate Officer/Principal | - | 20-11-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jon Saxe
BRD | Director/Board Member | 88 | 00-05-31 |
Jerry Gin
BRD | Director/Board Member | 81 | 16-02-29 |
Shawn Singh
CEO | Chief Executive Officer | 61 | 99-12-31 |
Chairman | 58 | 21-07-20 | |
Ann Cunningham
BRD | Director/Board Member | 56 | 19-01-09 |
Joanne Curley
BRD | Director/Board Member | 56 | 21-04-22 |
Mary Rotunno
BRD | Director/Board Member | 64 | 21-07-05 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 27,029,731 | 26,971,854 ( 99.79 %) | 4,522 ( 0.0167 %) | 99.79 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.18% | 121M | |
+3.40% | 108B | |
+10.96% | 104B | |
+1.28% | 22.33B | |
-12.00% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.82% | 17.64B | |
+4.90% | 14.05B | |
+34.78% | 12.51B |
- Stock Market
- Equities
- VTGN Stock
- Company Vistagen Therapeutics, Inc.